A report from the Roche ‘Excellence in Lung Cancer Diagnosis: Impact on the Patient Pathway’ meeting held in Nottingham last February, an event supported by a wide range of experts from across the UK.
According to Cancer Research UK (CRUK), lung cancer is the third most common cancer in the UK, after breast and prostate cancer, and is responsible for over 35,000 deaths per year.1 Over the past decade, huge strides have been made in terms of survival and quality of life for lung cancer patients. We now have a better understanding of the biology of lung cancer and of the genomic aberrations that influence the pathophysiology of the disease. As a result, a number of predictive biomarkers are now used to inform appropriate treatment pathways for patients.2
With rapidly evolving technologies, the need for education, communication and collaboration between disciplines has never been stronger. In February 2019, Roche Diagnostics brought together key opinion-leaders and stakeholders in the area of lung cancer diagnosis and treatment to explore how the combination of new biomarkers, technological advances, targeted therapies and informatics are transforming healthcare.
Immunohistochemistry in the classification of lung cancer
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.